{"id":22505,"date":"2023-09-14T11:31:12","date_gmt":"2023-09-14T15:31:12","guid":{"rendered":"https:\/\/www.mesotheliomahope.com\/?p=22505"},"modified":"2023-09-15T13:08:25","modified_gmt":"2023-09-15T17:08:25","slug":"truc-t-cell-new-immunotherapy","status":"publish","type":"post","link":"https:\/\/www.mesotheliomahope.com\/blog\/truc-t-cell-new-immunotherapy\/","title":{"rendered":"T Cell Receptor Fusion Constructs (TRuC): The Latest in Mesothelioma Immunotherapy Research"},"content":{"rendered":"

Mesothelioma<\/a> is a rare and aggressive cancer affecting the thin lining around sensitive parts of the body including the lungs, heart, and abdomen. Because it is so aggressive, researchers are constantly looking for newer, more effective treatments.<\/p>\n

T cell receptor fusion construct (TRuC) T cell therapy is one treatment currently being studied in clinical trials that is showing great promise. This treatment strengthens T cells\u2019 ability to attack solid mesothelioma tumors<\/strong> and has demonstrated success in the early phases of research.<\/p>\n

Learn more about what researchers say could be a favorable treatment<\/a> to shrink mesothelioma tumors, even for patients who have had little success with other therapies.<\/p>\n

What Is T Cell Receptor Fusion Constructs (TRuC) Therapy?<\/h2>\n

TRuC T cell therapy is an immunotherapy<\/a> that uses modified T cells to target mesothelioma tumors.<\/p>\n

T cells are critical cells that allow the immune system to target and kill dangerous infected cells. However, mesothelioma cancer cells can often sneak past the body’s natural defenses. By modifying T cells, immunotherapy stimulates the immune system fight off cancer cells.<\/p>\n

Immunotherapy has been an exciting new development for multimodal mesothelioma treatment plans<\/a> for several years, and TRuC T cell therapy, also called gavocabtagene autoleucel (gavo-cel), could join the list of treatment options because it can specifically target solid tumors that develop from mesothelioma and lung cancer<\/a>.<\/p>\n

How TRuC T Cell Therapy Targets Mesothelioma Tumors<\/h2>\n

Here\u2019s a breakdown of how this new T cell therapy can target solid tumors:<\/strong><\/p>\n

    \n
  1. Doctors encode T cells:<\/strong> Through a blood sample, mesothelioma doctors<\/a> remove T cells so they can be encoded with T cell receptor fusion construct (TRuC), which is a fusion protein made up of both the mesothelin antibody (MH1) and the T cell activator protein (CD3).<\/li>\n
  2. Modified T cells detect mesothelin:<\/strong> With bolstered proteins, these T cells are reintroduced into the body to detect mesothelin(MSLN)-specific tumors and activate a strong attack against tumor cells to kill them.<\/li>\n
  3. T cells continue to control cancer cells:<\/strong> For months after the initial injection of the T cells, they will keep immune system working against tumor cells, whether by preventing new cells from growing or fighting large tumors.<\/li>\n<\/ol>\n

    Results of TRuC T Cell Therapy Clinical Trial<\/h2>\n

    A clinical trial<\/a> led by researchers from the National Cancer Institute Center for Cancer Research examined how TRuC T cell therapy worked for 32 patients between May 2019 and May 2022. The trial participants included 23 mesothelioma patients, 8 ovarian cancer patients, and 1 patient with bile duct cancer.<\/p>\n

    Results from the trial showed:<\/strong><\/p>\n

      \n
    • 30% of patients had a reduction in tumor size<\/li>\n
    • 20% were able to be evaluated for tumor response (after tumors had not responded to, on average, 5 other types of treatment)<\/li>\n
    • 13% had a long-lasting reduction in tumor size<\/li>\n<\/ul>\n

      Those with the most durable response saw results that continued up to a year after treatment.<\/strong><\/p>\n

      One of the lead researchers, Dr. Raffitt Hassan<\/a>, told the Center for Cancer Research, \u201cThis is one of the very few adoptive cell therapies in solid tumors that has shown objective tumor regressions, [proving] that TruC T cells work and we can get responses<\/strong>, even in heavily pretreated patients.\u201d<\/p>\n